Sangamo Therapeutics Inc (LTS:0R1D)
$ 0.4022 -0.1078 (-21.14%) Market Cap: 85.83 Mil Enterprise Value: 62.23 Mil PE Ratio: 0 PB Ratio: 1.49 GF Score: 38/100

Sangamo Therapeutics Inc at Bank of America Global Healthcare Conference Transcript

May 09, 2023 / 04:20PM GMT
Release Date Price: $1.29 (-6.86%)
Gregory Allen Harrison
BofA Securities, Research Division - Analyst

[Day one] of the Bank of America Healthcare Conference. I'm Greg Harrison, one of the biotech analysts here at BofA. And today, we're lucky to have Sangamo Therapeutics with Sandy Macrae, Chief Executive Officer. Thank you for joining us.

Let's move right into Q&A.

Alexander D. Macrae
Sangamo Therapeutics, Inc. - CEO, President & Director

Please.

Questions & Answers

Gregory Allen Harrison
BofA Securities, Research Division - Analyst

The Fabry program and the ongoing Phase I/II STAAR study, for those new to the story, maybe you could review the current status of the program, and how your treatment could be differentiated compared to standard of care?

Alexander D. Macrae
Sangamo Therapeutics, Inc. - CEO, President & Director

Well, we're really excited about the Fabry program. We're best-in-class, first-in-class, and now only in-class as the other gene therapies have all

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot